14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HHS vs HVT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Haverty Furniture Companies, Inc. (HVT) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas HVT carries 57.9/100 (HOLD) at $25.39 (12.7x Forward P/E, 3.1% operating margin).
Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. HVT 57.9/100 HOLD), HVT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (3.1% vs. -3.2% operating margin) and revenue trajectory (+4.5% vs. -1.7% YoY).
Technical & Structure Timing Caution: HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2); meanwhile HVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs HVT. Trailing 12-month operating profitability (HHS -3.2% vs HVT 3.1%) and valuation multiples (HHS 14.3x vs HVT 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Home Improvement Retail value chain with $405.3M market capitalization and 3.1% operating margin.
OpEx & R&D Reinvestment57.7% of Rev ($455M)
90D Engineering Disclosures0 Published
Investor FAQ HHS vs HVT Key Questions & Quantitative Answers
As of Nov 16, 2026, Haverty Furniture Companies, Inc. (HVT) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas HVT carries 57.9/100 (HOLD) at $25.39 (12.7x Forward P/E, 3.1% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. HVT 57.9/100 HOLD), HVT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (3.1% vs. -3.2% operating margin) and revenue trajectory (+4.5% vs. -1.7% YoY). Technical & Structure Timing Caution: HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2); meanwhile HVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HVT leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with HVT at +4.5% YoY revenue growth and +39.3% YoY earnings growth on $789M TTM revenue (60.8% gross margin, 3.1% operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus $789M for HVT. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 57.7% of Rev ($455M) (0 disclosures) for HVT.
HVT screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas HVT trades at 12.7x Forward P/E, 17.6x Trailing P/E, 0.91x PEG, and 0.5x EV/Revenue (6.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus HVT (8.1% ROE) capital efficiency.
In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, HVT carries 35.3% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.99β · 53% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.